HealthQuill Fibrosis
A new artificial intelligence model developed by researchers at Johns Hopkins University can predict whether a patient is likely to experience a cardiac arrest much better than doctors, who rely on limited clinical symptoms.
Health Medical Research

Doctors step aside, AI can predict patients at risk of cardiac arrest

HQ Team July 7, 2025: A new artificial intelligence model developed by researchers at Johns Hopkins University can predict whether patients are likely.

Read More
Madrigal Pharmaceuticals EU Limited's therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing authorisation in the European Union. 
Drugs Health Medical

Madrigal’s therapy to treat MASH in adults gets EU’s initial nod

HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing.

Read More
More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver disease due to sedentary lifestyles, posing a significant health challenge, according to a study.
Drugs Health Research

In Hyderabad, India, 84% of IT workers have non-alcoholic fatty liver

HQ Team April 24, 2025: More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver.

Read More
US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria.
Drugs Health Pharma

Gene editing kills female mosquitoes that spread malaria

HQ Team July 10, 2023: US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria..

Read More
fibrosis therapy pact
Medical Pharma

Mediar bags $105 mn from big pharmas to pursue fibrosis treatments

Mediar Therapeutics gets $105 million financing from Novartis, Pfizer, Eli Lilly and Bristol Myers to advance portfolio of first-in-class fibrosis therapies.

Read More
Redx Pharma, based in the UK and Jounce Therapeutics, US, will merge in an all-share transaction worth $425 million to establish a new entity focusing on treating cancers and fibrosis.
Drugs Pharma

Redx, Jounce to merge in a $425 million all-share deal

Redx Pharma, based in the UK and Jounce Therapeutics, US, will merge in an all-share transaction worth $425 million to establish a new.

Read More